WO2001044198A8 - Amphiphile chinolylpolyamine als transfermittel für biologisch aktive makromoleküle - Google Patents

Amphiphile chinolylpolyamine als transfermittel für biologisch aktive makromoleküle

Info

Publication number
WO2001044198A8
WO2001044198A8 PCT/DE2000/004443 DE0004443W WO0144198A8 WO 2001044198 A8 WO2001044198 A8 WO 2001044198A8 DE 0004443 W DE0004443 W DE 0004443W WO 0144198 A8 WO0144198 A8 WO 0144198A8
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
quinolylpolyamines
amphiphilic
transfer agents
active macromolecules
Prior art date
Application number
PCT/DE2000/004443
Other languages
English (en)
French (fr)
Other versions
WO2001044198A1 (de
Inventor
Oliver Keil
Original Assignee
G O T Ges Fuer Therapieoptimie
Oliver Keil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G O T Ges Fuer Therapieoptimie, Oliver Keil filed Critical G O T Ges Fuer Therapieoptimie
Priority to JP2001544688A priority Critical patent/JP2003516970A/ja
Priority to EP00993406A priority patent/EP1244630A1/de
Priority to AU28304/01A priority patent/AU2830401A/en
Publication of WO2001044198A1 publication Critical patent/WO2001044198A1/de
Publication of WO2001044198A8 publication Critical patent/WO2001044198A8/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die vorliegende Erfindung betrifft amphiphile Polyamine und deren Salze, welche befähigt sind, Biopolymere wie DNA, RNA, Antisense-Oligonukleotide, Ribozyme, Proteine und Peptide zu komplexieren und in eukaryotische Zellen einzuschleusen. Hierbei erwiesen sich Polyaminochinolin-Derivate, welche mit lipophilen Gruppen modifiziert sind, als besonders geeignete Substanzklasse. Aufgrund ihrer Eigenschaft mit biologisch aktiven Molekülen, wie zum Beispiel DNA oder RNA, Aggregate zu bilden, eignen sich diese Verbindungen insbesondere für Anwendungen in der Gentherapie, aber auch für diagnostische Zwecke.
PCT/DE2000/004443 1999-12-17 2000-12-13 Amphiphile chinolylpolyamine als transfermittel für biologisch aktive makromoleküle WO2001044198A1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001544688A JP2003516970A (ja) 1999-12-17 2000-12-13 両親媒性ポリアミン、その使用およびその合成方法
EP00993406A EP1244630A1 (de) 1999-12-17 2000-12-13 Amphiphile chinolylpolyamine als transfermittel für biologisch aktive makromoleküle
AU28304/01A AU2830401A (en) 1999-12-17 2000-12-13 Amphiphilic polyamines, the use and method for synthesis thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19960924A DE19960924C2 (de) 1999-12-17 1999-12-17 Amphiphile Polyamine, deren Anwendungen
DE19960924.1 1999-12-17

Publications (2)

Publication Number Publication Date
WO2001044198A1 WO2001044198A1 (de) 2001-06-21
WO2001044198A8 true WO2001044198A8 (de) 2001-10-04

Family

ID=7933047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/004443 WO2001044198A1 (de) 1999-12-17 2000-12-13 Amphiphile chinolylpolyamine als transfermittel für biologisch aktive makromoleküle

Country Status (6)

Country Link
US (1) US20030109699A1 (de)
EP (1) EP1244630A1 (de)
JP (1) JP2003516970A (de)
AU (1) AU2830401A (de)
DE (1) DE19960924C2 (de)
WO (1) WO2001044198A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036557A1 (en) * 2009-09-22 2011-03-31 The University Of British Columbia Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
WO2011115555A1 (en) * 2010-03-16 2011-09-22 Ge Healthcare Bio-Sciences Ab System for improved delivery of gene modulating compounds
CN108424434B (zh) * 2017-02-13 2020-07-28 四川大学 氯喹胆固醇衍生物及其制备方法和用途
CN109912811B (zh) * 2019-03-29 2021-04-06 安徽省农业科学院蚕桑研究所 一种双亲性丝胶蛋白聚合物的制备方法与聚合物的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU43783A1 (de) * 1962-06-22 1963-07-22
FR2581382B1 (fr) * 1985-05-06 1987-06-26 Sanofi Sa Derives n-(quinolyl) glycinamides, leur procede de preparation et leur application therapeutique en tant que psychotropes
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
US5312921A (en) * 1990-03-14 1994-05-17 Regents Of The University Of California Dyes designed for high sensitivity detection of double-stranded DNA
EP0632722A4 (de) * 1992-03-20 1997-07-30 Baylor College Medicine In form-imc-beschichtungsverfahren mit doppelaushaertung zur herstellung von abriebfesten,beschichteten,thermoplastischen gegenstaenden.
DE69433519T2 (de) * 1993-07-14 2004-11-11 The Regents Of The University Of California, Oakland Sich selbst zusammensetzendes polynukleotid-abgabesystem, das dendrimer-polykationen enthält
US5780009A (en) * 1995-01-20 1998-07-14 Nexia Biotechnologies, Inc. Direct gene transfer into the ruminant mammary gland
DE19610805A1 (de) * 1996-03-19 1997-09-25 Sigrun Finke Verfahren zum Einschleusen von Makromolekülen in Eukaryontenzellen
US6479504B1 (en) * 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases

Also Published As

Publication number Publication date
AU2830401A (en) 2001-06-25
DE19960924C2 (de) 2002-08-01
JP2003516970A (ja) 2003-05-20
US20030109699A1 (en) 2003-06-12
WO2001044198A1 (de) 2001-06-21
EP1244630A1 (de) 2002-10-02
DE19960924A1 (de) 2001-07-05

Similar Documents

Publication Publication Date Title
Kumar et al. DNA nanotechnology for cancer therapy
Lee et al. Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2
Zhang et al. Poly (L-lysine) nanostructured particles for gene delivery and hormone stimulation
CY1118963T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
Romøren et al. The influence of formulation variables on in vitro transfection efficiency and physicochemical properties of chitosan-based polyplexes
DE69433519T2 (de) Sich selbst zusammensetzendes polynukleotid-abgabesystem, das dendrimer-polykationen enthält
Bozkir et al. Chitosan–DNA nanoparticles: effect on DNA integrity, bacterial transformation and transfection efficiency
EP1397200B1 (de) Auflösbare nano- und mikrokapseln, verfahren zu ihrer herstellung sowie ihre verwendung
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
JP2006525796A5 (de)
DE60029829D1 (de) Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung
WO2007073489A3 (en) Molecules for gene delivery and gene therapy, and methods of use thereof
ATE289630T1 (de) Transfer von mrnas unter verwendung von polykationischen verbindungen
Gagnon et al. Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide–oligospermine conjugates
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
JPH06506834A (ja) 閉鎖アンチセンス及びセンスオリゴヌクレオチドとそれらの適用
CN108779074A (zh) 植物病毒移动蛋白和其使用方法
EP1764089A1 (de) Serumstabile liposomale Formulierungen enthaltend amphotere II Lipidmischungen
CY1109744T1 (el) Συζυγη και μεθοδοι για την παραγωγη τους, και η χρηση τους για την μεταφορα μοριων δια μεσου βιολογικων μεμβρανων
Junghans et al. Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles
WO2003057164A3 (en) Compounds for delivering substances into cells
Nomani et al. Physicochemical and biological properties of self-assembled antisense/poly (amidoamine) dendrimer nanoparticles: the effect of dendrimer generation and charge ratio
DE69804463D1 (de) Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie
Ge et al. Rational construction of protein-mimetic nano-switch systems based on secondary structure transitions of synthetic polypeptides
Soliman et al. Responsive polyelectrolyte complexes for triggered release of nucleic acid therapeutics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 544688

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000993406

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10149732

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000993406

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000993406

Country of ref document: EP